edrophonium has been researched along with tacrolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adachi, Y; Furukawa, Y; Iwasa, K; Kuriyama, N; Kuwabara, S; Matsui, M; Murai, H; Nakamura, Y; Nomura, Y; Sakai, Y; Yoshikawa, H | 1 |
1 review(s) available for edrophonium and tacrolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for edrophonium and tacrolimus
| Article | Year |
|---|---|
Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018.
Topics: Activities of Daily Living; Adult; Aged; Autoantibodies; Edrophonium; Esterases; Female; Humans; Immunoglobulins, Intravenous; Japan; Male; Middle Aged; Myasthenia Gravis; Prednisolone; Surveys and Questionnaires; Tacrolimus; Thymectomy; Thymoma; Thymus Neoplasms | 2022 |